Felzartamab vs STI-6129
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Felzartamab
Developed by Biogen and partners
NCT03952091 · Phase 3 · completed
This was a large (n=289), randomized, active-controlled Phase 3 trial using a well-accepted hard clinical endpoint (progression-free survival), and the drug combination showed a statistically significant improvement over the active comparator. However, the trial was conducted completely open-label with no blinding of patients or investigators, which limits confidence in the result despite its objective endpoint and statistical significance.
Reported efficacy
Progression-free survival (PFS) (18.4 months(Active) 30.7 months(experimental)): Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035) (met)
Result source: NCT03952091
STI-6129
Developed by Sorrento Therapeutics, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05565807 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Felzartamab | STI-6129 |
|---|---|---|
| PFS, median | —Not posted · NCT03952091 | —Not reported |
| OS, median | —Not posted · NCT03952091 | —Not reported |
| ORR | —Not posted · NCT03952091 | —Not reported |
| VGPR or better | —Not posted · NCT03952091 | —Not reported |
| MRD negativity | —Not posted · NCT03952091 | —Not reported |
PFS, median
- Felzartamab
- —Not posted · NCT03952091
- STI-6129
- —Not reported
OS, median
- Felzartamab
- —Not posted · NCT03952091
- STI-6129
- —Not reported
ORR
- Felzartamab
- —Not posted · NCT03952091
- STI-6129
- —Not reported
VGPR or better
- Felzartamab
- —Not posted · NCT03952091
- STI-6129
- —Not reported
MRD negativity
- Felzartamab
- —Not posted · NCT03952091
- STI-6129
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
STI-6129: no structured comparison results are available for Multiple Myeloma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Felzartamab's landscape · STI-6129's landscape